GlassScriptPhysician profile
Richard Frank Walker
NPI 1760488910
$606.44
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $76.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $107.32 | 2019-2020 | |
| Baxter Healthcare | $93.26 | 2019 | |
| Opko Pharmaceuticals, LLC | $80.75 | 2019 | |
| Mallinckrodt Enterprises LLC | $64.38 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $56.00 | 2019-2020 | |
| Vifor Pharma, INC. | $54.86 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $33.47 | 2019 | |
| Allergan, INC. | $25.57 | 2019 | |
| Daiichi Sankyo INC. | $24.10 | 2019 | |
| Akebia Therapeutics INC | $19.29 | 2019 | |
| Genzyme Corporation | $19.23 | 2019 | |
| Fresenius USA Marketing, INC. | $14.31 | 2019 | |
| Horizon Therapeutics Plc | $13.90 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.